V
Viridian Therapeutics D
D
VRDN
22.470
USD
-0.27
(-1.19%)
مفتوح الان
حجم التداول
3,761
الربح لكل سهم
-5
العائد الربحي
-
P/E
-7
حجم السوق
2,545,677,284
المقالات
العنوان: Viridian Therapeutics
القطاع: الرعاية الصحية
الصناعة: Biotechnology
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibodytargeting IGF-1R intravenously administered for the treatment of TED.